The spinal cord stimulators market size is estimated to register a revenue of US$ 5,441.4 million by 2033. Our healthcare experts opine that spinal cord stimulator suppliers can expect a promising CAGR of 7.2% through 2033, with a present valuation of US$ 2,702.7 million in 2023.
Spinal Cord Stimulators Market Trends
Clinical Studies to Enhance the Market Demand for Spinal Cord Stimulators
Key players are initiating clinical studies to further the market expansion. For instance, ANEUVO, a platform and therapy development firm, recently commenced the clinical study of the ExaStim TSS system, a wirelessly controlled neuromodulation system engineered for transcutaneous spinal cord stimulation (TSS). The study intends to research the safety and efficacy of ExaStim in combination with conventional rehabilitation therapy for patients with upper extremity paralysis.
TSS is an emerging neuromodulation therapy with the scope to assist individuals suffering from SCI to better their motor function. ExaStim therapy stimulates the spinal cord to modulate neural networks to improve motor function. Initial research suggests that non-invasive spinal stimulation may assist individuals with SCI in recovering lost motor function and improving their functional independence.
Recent Advances in Spinal Rehabilitation Technology
The market is observing significant advances in spinal rehabilitation therapy and technology. For instance, the American Congress of Rehabilitation Medicine (ACRM) conference in 2022 exhibited several new technologies and trends in spinal cord rehabilitation. These are expected to enhance the management of spinal cord injury (SCI).
One of the recent innovations includes neuromodulation devices. These involve the usage of electrodes on the brain, peripheral nerves, or the spinal cord. It functions by actively stimulating nerves to develop a natural biological response or by using targeted pharmaceutical agents in small doses straight to the site. The latest evidence has showcased that almost 50% of patients have stated enhanced pain management.
| Attributes | Details |
|---|---|
| Spinal Cord Stimulators Market Size, 2022 | US$ 2,550.3 million |
| Spinal Cord Stimulators Market Size, 2023 | US$ 2,702.7 million |
| Spinal Cord Stimulators Market Size, 2033 | US$ 5,441.4 million |
| Value CAGR (2023 to 2033) | 7.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The spinal cord stimulators market is estimated to expand at a higher CAGR of 7.2% in the forecast period, in comparison to the 5.8% CAGR observed in the historical period.
| Spinal Cord Stimulators Market Size (2018) | US$ 2,037.50 million |
|---|---|
| Spinal Cord Stimulators Market Size (2022) | US$ 2,550.3 million |
| Spinal Cord Stimulators Market (CAGR 2018 to 2022) | 5.8% |
According to the estimates by the National Spinal Cord Injury Statistical Center, chronic diseases have now doubled in the past few years. In the United States alone, 54 incidences of injuries in every million get listed under SCI owing to surged injuries and traumas associated with spinal procedures and treatments. The spinal cord stimulator industry is expected to swell due to rising cases of chronic diseases in the upcoming years.
The industry is projected to widen as awareness about the advantages of these technologies to alleviate pain becomes widespread. The schemes and policies offered by the government to profit the elderly population and underprivileged people by getting treated at reasonable costs are significant factors leading to market expansion.
Increasing cases of spinal cord injuries are giving way to several treatment devices, like non-fusion spinal devices, spinal cord stimulators, neurostimulators, etc. The demand outlook for non-fusion spinal devices is driven by the surging aging population and increasing preference for minimally invasive surgery treatments.
In the following table, FMI analysts analyze the spinal cord stimulators market in comparison to the functional electrical stimulation market and neurostimulation market. As per the recent projections, the neurostimulation market is expected to expand at a greater CAGR of 11.5% through 2033. In terms of revenue, the neurostimulation market is expected to be worth US$ 7.22 billion in 2023, significantly greater than the other two compared markets.
Spinal Cord Stimulators Market
| Attributes | Spinal Cord Stimulators Market |
|---|---|
| CAGR (2023 to 2033) | 7.2% |
| Market Value (2023) | US$ 2,702.7 million |
| Growth Factors |
|
| Future Opportunities | Surging return on investment in recent technologies is expected to increase the scope of SCS devices. |
| Market Trends | Emergence of the latest spinal cord stimulation technologies |
Functional Electrical Stimulation Market
| Attributes | Functional Electrical Stimulation Industry |
|---|---|
| CAGR (2023 to 2033) | 4.1% |
| Market Value (2023) | US$ 620.9 million |
| Growth Factors |
|
| Future Opportunities | Growing importance of pain management devices in several areas of medicine |
| Market Trends | Surging technological innovations |
Neurostimulation Market
| Attributes | Neurostimulation Market |
|---|---|
| CAGR (2023 to 2033) | 11.5% |
| Market Value (2023) | US$ 7.22 billion |
| Growth Factors |
|
| Future Opportunities | Increasing adoption of brain neurostimulation devices for an effective treatment of age-related and neurotic symptoms |
| Market Trends | The development of implantable neurostimulation devices drives the growth of the global neurostimulation market. |
Principal Consultant
| Country/ Region | Value Share (2022) |
|---|---|
| North America | 75.2% |
| Europe | 14.8% |
| The United States | 73.1% |
| Germany | 2.3% |
| Japan | 4.9% |
The spinal cord stimulators are instrumental in treating chronic neuropathic pain refractory. This treatment option is used when intractable chronic pain has not improved with conventional treatment modalities. Several SCS/neuromodulation recipients include women of childbearing age who may become pregnant. As per the latest market estimates, the North America market for spinal cord stimulators holds the maximum market share of around 75.2%.
The United States spinal cord stimulators market is expected to acquire a market value of about 73.1% in 2022. The market development can be attributed to the utilization patterns that show a drastic surge in spinal cord stimulation trials. Moreover, due to ongoing research and study, the medical literature exhibits the efficacy of spinal cord stimulation in alleviating chronic pain and improving quality of life and cost-utility.
The market in the United States is also thriving due to Medicare-approved SCS operations. From 2000 to 2019, there were 9,92,372 Medicare-approved percutaneous cord stimulator operations. Total open spinal cord stimulator operations, in this duration that were Medicare-approved included somewhere around 99,736. In 2019, Medicare paid US$ 1.02 billion and US$ 145 million in reimbursement to physicians for percutaneous spinal cord stimulator and open spinal cord stimulator operations, respectively.
The Europe market is expected to acquire about 14.8% in 2023. The region is led by Germany, which has a market contribution of 2.3% on a global scale. The regional market is catalyzed by the increasing cases of failed back surgery syndrome, also known as postlaminectomy syndrome (PLS). The treatment of this disorder entails the deployment of spinal cord stimulators. With the advent of the latest technologies, the demand for SCS devices has dramatically surged to alleviate axial pain effectively. Rising demand for industry-sponsored trials for improved outcomes is expected to consolidate the market.
The United Kingdom market is expected to thrive at a CAGR of 6.9% through 2033. Throughout the forecast period, the soaring presence of highly qualified healthcare professionals, surging awareness about SCS, and fueling healthcare funding are expected to advance the market growth.
The Japan market for spinal cord stimulators is expected to acquire a market share of around 4.9% in 2023. The market is experiencing a surge in patients suffering from neuropathic pain and choosing spinal procedures due to injuries and trauma. Moreover, Japan's health ministry has permitted induced pluripotent stem cells (iPS) to treat spinal cord injuries. iPS is being studied at Keio University in Japan, and it is considered one of the most significant treatment plans in regenerative medicine techniques.
The technique of iPS cells has escalated the expectations of mobility and function of paralyzed muscles. Consequently, this fueled the demand for the growth of spinal cord stimulators.
The Asia Pacific spinal cord stimulators market is expected to expand at a notable CAGR. The region is being supported by the growth in the emerging economies of the continent, particularly China and India, which show growth rates of 5.8% and 5.5% CAGRs, respectively. Since chronic pain is a critical social burden in Asian countries, the market for spinal cord stimulators is surging at an elevated rate. This is because spinal cord stimulation (SCS) is a promising treatment for refractory pain.
Analysts at FMI have predicted positive future trends for the uptake of spinal cord stimulators by hospitals, clinics, and ambulatory surgical centers. As research in this field is gaining high traction, and different regional organizations are coming forward to provide financial support for the said research, the market scope is expected to amplify over the forecast period.
China is expected to facilitate the establishment of novel indications for SCS, considering that at least one of their active trials is feasibility research of epidural stimulation in patients suffering from disorders of consciousness.
The spinal cord stimulators market in Australia is expected to expand at a CAGR of 6.9% through 2033. The increasing commitment from the public, as well as the private sector, is critical in obtaining treatments from bench to bedside. Researchers have predicted the requirement of US$ 10 to 20 million in research investment to boost the adoption rate of spinal cord stimulation by all Australians suffering from spinal cord injury (SCI). In Australia, around 20,800 Australians have been diagnosed with SCI as of 2020, boosting the uptake of treatment options.
Despite the high cost of delivery of treatment plans, their return on investment is quite high. For instance, the new spinal cord stimulation treatment, which requires US$ 20 million of investment, can gain a cost saving of US$ 1.3 billion, thus resulting in a benefit-cost ratio of 1.96.
The rechargeable stimulator devices are gaining high traction. As per the analysts at FMI, the segment is expected to occupy a market share of around 67.7% in 2023. Factors like adaptability, affordability, and ability to control pain via wireless remote procedures are attributed to the surging adoption of these devices.
| Top Segment | Rechargeable Stimulator Devices |
|---|---|
| Market Share in 2023 | 67.7% |
Rechargeable stimulator devices facilitate curbing neuropathic pain by moderately electrically stimulating the spinal cord near pain points. Additionally, the battery of these devices is easy to replace.
The new product launches by prominent firms and the surge in patients with neuropathic and chronic pain are fueling the market growth. As reported by the NIH report on rechargeable and non-rechargeable systems in 2021, the median longevity of rechargeable devices was relatively greater than that of non-rechargeable devices purchased at similar costs.
Failed back surgery syndrome is expected to account for around 65.6% of the global market share in 2023. As per the research undertaken in North America, Latin America, and Europe, 44.6% cases of overall SCI cases were of failed back surgery syndrome (FBSS).
| Top Segment | Failed Back Surgery Syndrome |
|---|---|
| Market Share in 2023 | 65.6% |
Increasing advances in the spinal cord stimulation technique by the top investors are expected to lead the market growth. Increasing healthcare infrastructure and mounting healthcare funding are also driving the growth of this segment.
The ambulatory surgical centers (ASC) segment led the market by 59.1% market share. This segment has amassed significant revenue on account of cost-effective procedures and shorter stay periods.
| Top Segment | Ambulatory Surgical Centers |
|---|---|
| Market Share in 2023 | 59.1% |
Apart from this, manufacturers educate citizens about the benefits of SCS devices, which also contributes to the increase in patients seeking diagnostic procedures to overcome any challenge later on. The surge in the minimally invasive surgeries operated in ASCs is also fueling the sales in ambulatory surgical centers.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key players in the market are going for M&A methods to gain a swift and low-risk entry in the global spinal cord stimulators market. M&A also helps widen the scope of the product portfolio. Additionally, active companies are emphasizing the research and development of new technologies to effectively manage pain. This creates a high preference for the leading players.
New Developments Taken Place in the Market
Market Players:
The spinal cord stimulators market is worth US$ 2,702.7 million in 2023.
The market is expected to expand at a CAGR of 7.2% through 2033.
The United States leads the spinal cord stimulators market.
Rechargeable spinal cord stimulators are witnessing high preference by end users.
Boston Scientific Corp, Greatbatch, Inc., and Saluda Medical Pty Ltd. are the key competitors of SCS.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Products 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Products, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Products, 2023 to 2033 5.3.1. Rechargeable 5.3.2. Non-Rechargeable 5.4. Y-o-Y Growth Trend Analysis By Products, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Products, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Application, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Failed back Surgery Syndrome 6.3.2. Complex Regional Pain Syndrome 6.3.3. Ischemic Limb pain 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Hospitals 7.3.2. Ambulatory Surgical Centers 7.3.3. Clinics 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Products 9.2.3. By Application 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Products 9.3.3. By Application 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Products 10.2.3. By Application 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Products 10.3.3. By Application 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. U.K. 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Products 11.2.3. By Application 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Products 11.3.3. By Application 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Products 12.2.3. By Application 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Products 12.3.3. By Application 12.3.4. By End User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Products 13.2.3. By Application 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Products 13.3.3. By Application 13.3.4. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Products 14.2.3. By Application 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Products 14.3.3. By Application 14.3.4. By End User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Products 15.2.3. By Application 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Products 15.3.3. By Application 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. U.S. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Products 16.1.2.2. By Application 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Products 16.2.2.2. By Application 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Products 16.3.2.2. By Application 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Products 16.4.2.2. By Application 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Products 16.5.2.2. By Application 16.5.2.3. By End User 16.6. U.K. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Products 16.6.2.2. By Application 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Products 16.7.2.2. By Application 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Products 16.8.2.2. By Application 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Products 16.9.2.2. By Application 16.9.2.3. By End User 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Products 16.10.2.2. By Application 16.10.2.3. By End User 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Products 16.11.2.2. By Application 16.11.2.3. By End User 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Products 16.12.2.2. By Application 16.12.2.3. By End User 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Products 16.13.2.2. By Application 16.13.2.3. By End User 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Products 16.14.2.2. By Application 16.14.2.3. By End User 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Products 16.15.2.2. By Application 16.15.2.3. By End User 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Products 16.16.2.2. By Application 16.16.2.3. By End User 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Products 16.17.2.2. By Application 16.17.2.3. By End User 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Products 16.18.2.2. By Application 16.18.2.3. By End User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Products 16.19.2.2. By Application 16.19.2.3. By End User 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Products 16.20.2.2. By Application 16.20.2.3. By End User 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Products 16.21.2.2. By Application 16.21.2.3. By End User 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Products 16.22.2.2. By Application 16.22.2.3. By End User 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Products 16.23.2.2. By Application 16.23.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Products 17.3.3. By Application 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Medtronic Public Limited Company 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.1.5.2. Product Strategy 18.1.1.5.3. Channel Strategy 18.1.2. Boston Scientific Corp 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.2.5.2. Product Strategy 18.1.2.5.3. Channel Strategy 18.1.3. St Jude Medical LLC and Nevro Corp 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.3.5.2. Product Strategy 18.1.3.5.3. Channel Strategy 18.1.4. Nuvectra Corporation and Stimwave 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.4.5.2. Product Strategy 18.1.4.5.3. Channel Strategy 18.1.5. Neurosigma Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.5.5.2. Product Strategy 18.1.5.5.3. Channel Strategy 18.1.6. Synapse Biomedical Inc 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.6.5.2. Product Strategy 18.1.6.5.3. Channel Strategy 18.1.7. Abbott Laboratories 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.7.5.2. Product Strategy 18.1.7.5.3. Channel Strategy 18.1.8. Beijing PINS Medical Co., Ltd 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.8.5.2. Product Strategy 18.1.8.5.3. Channel Strategy 18.1.9. Cirtec Medical Corporation 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.9.5.2. Product Strategy 18.1.9.5.3. Channel Strategy 18.1.10. Gimer Medical 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.10.5.2. Product Strategy 18.1.10.5.3. Channel Strategy 18.1.11. Bluewind Medica 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.11.5.2. Product Strategy 18.1.11.5.3. Channel Strategy 18.1.12. Bioinduction 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.12.5.2. Product Strategy 18.1.12.5.3. Channel Strategy 18.1.13. Greatbatch, Inc 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 18.1.13.5.2. Product Strategy 18.1.13.5.3. Channel Strategy 18.1.14. Saluda Medical Pty Ltd. 18.1.14.1. Overview 18.1.14.2. Product Portfolio 18.1.14.3. Profitability by Market Segments 18.1.14.4. Sales Footprint 18.1.14.5. Strategy Overview 18.1.14.5.1. Marketing Strategy 18.1.14.5.2. Product Strategy 18.1.14.5.3. Channel Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Spinal Cord Stimulators Market
